Trials / Completed
CompletedNCT02710604
Phase 2, Multiple Ascending Dose Proof of Concept Study
A Phase 2, Randomized, Open-label, Ascending, Sequential Dose Group, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of CMX157 in HBV-infected Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- ContraVir Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.
Detailed description
This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels in hepatitis B virus(HBV) infected subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CMX157 | tablet |
| DRUG | TDF | 300mg tablet |
Timeline
- Start date
- 2016-05-01
- Primary completion
- 2017-07-18
- Completion
- 2017-07-18
- First posted
- 2016-03-17
- Last updated
- 2017-09-13
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT02710604. Inclusion in this directory is not an endorsement.